{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:31:32Z","timestamp":1785522692908,"version":"3.56.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00224099"],"award-info":[{"award-number":["RS-2023-00224099"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Trimethylamine N-oxide (TMAO), a gut microbiota-derived metabolite, is associated with cardiovascular disease (CVD) via pro-inflammatory and pro-atherogenic mechanisms. Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with a significantly increased risk of CVD, however, the role of TMAO in SLE remains unclear. This study aimed to assess the clinical significance of TMAO in patients with SLE, including analyses of precursor metabolites and gut microbiome. A total of 207 participants were enrolled, including 157 patients with SLE and 50 healthy controls. Serum TMAO levels were measured using ELISA, fecal precursor metabolites including trimethylamine (TMA) were quantified by\n                    <jats:sup>1<\/jats:sup>\n                    H-NMR spectroscopy, and gut microbiota composition was assessed using 16S rRNA sequencing. SLE patients with CVD had significantly higher TMAO levels than HC (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.028) and SLE patients without CVD (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.004). Serum TMAO (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.025) and fecal TMA (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.032) levels were positively correlated with the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology (SLICC\/ACR) damage index. Serum TMAO was negatively correlated with steroid dose (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.038). Distinct gut microbiota compositions were observed between SLE patients with and without CVD. TMAO is associated with cardiovascular disease and cumulative organ damage in SLE, potentially mediated by gut microbiome alterations and modulated by steroid therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-53011-7","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:54:43Z","timestamp":1779465283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical significance of gut microbiota-derived metabolite trimethylamine N-oxide in patients with systemic lupus erythematosus"],"prefix":"10.1038","volume":"16","author":[{"given":"Jiwon","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngjae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Gwang","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Jung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Jin","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Kyoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Ki","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"53011_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41584-025-01267-0","volume":"21","author":"E Pati\u00f1o-Martinez","year":"2025","unstructured":"Pati\u00f1o-Martinez, E. & Kaplan, M. J. Immunometabolism in systemic lupus erythematosus. Nat. Rev. Rheumatol. 21, 377\u2013395 (2025).","journal-title":"Nat. Rev. Rheumatol."},{"key":"53011_CR2","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","volume":"403","author":"A Hoi","year":"2024","unstructured":"Hoi, A., Igel, T., Mok, C. C. & Arnaud, L. Systemic lupus erythematosus. Lancet 403, 2326\u20132338 (2024).","journal-title":"Lancet"},{"key":"53011_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4078\/jrd.2023.0037","volume":"30","author":"JY Han","year":"2023","unstructured":"Han, J. Y., Cho, S. K. & Sung, Y. K. Epidemiology of systemic lupus erythematosus in Korea. J. Rheum. Dis. 30, 211\u2013219 (2023).","journal-title":"J. Rheum. Dis."},{"key":"53011_CR4","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1002\/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I","volume":"44","author":"JM Esdaile","year":"2001","unstructured":"Esdaile, J. M. et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 44, 2331\u20132337 (2001).","journal-title":"Arthritis Rheum."},{"key":"53011_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature09922","volume":"472","author":"Z Wang","year":"2011","unstructured":"Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57\u201363 (2011).","journal-title":"Nature"},{"key":"53011_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.atherosclerosis.2018.02.036","volume":"271","author":"LJ Kasselman","year":"2018","unstructured":"Kasselman, L. J., Vernice, N. A., DeLeon, J. & Reiss, A. B. The gut microbiome and elevated cardiovascular risk in obesity and autoimmunity. Atherosclerosis 271, 203\u2013213 (2018).","journal-title":"Atherosclerosis"},{"key":"53011_CR7","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1109400","volume":"368","author":"WH Tang","year":"2013","unstructured":"Tang, W. H. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 368, 1575\u20131584 (2013).","journal-title":"N. Engl. J. Med."},{"key":"53011_CR8","doi-asserted-by":"publisher","first-page":"e02481","DOI":"10.1128\/mBio.02481-14","volume":"6","author":"KA Romano","year":"2015","unstructured":"Romano, K. A., Vivas, E. I., Amador-Noguez, D. & Rey, F. E. Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. mBio 6, e02481 (2015).","journal-title":"mBio"},{"key":"53011_CR9","doi-asserted-by":"publisher","first-page":"21307","DOI":"10.1073\/pnas.1215689109","volume":"109","author":"S Craciun","year":"2012","unstructured":"Craciun, S. & Balskus, E. P. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc. Natl. Acad. Sci. U. S. A. 109, 21307\u201321312 (2012).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"53011_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cmet.2012.12.011","volume":"17","author":"BJ Bennett","year":"2013","unstructured":"Bennett, B. J. et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell. Metab. 17, 49\u201360 (2013).","journal-title":"Cell. Metab."},{"key":"53011_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cell.2016.02.011","volume":"165","author":"W Zhu","year":"2016","unstructured":"Zhu, W. et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165, 111\u2013124 (2016).","journal-title":"Cell"},{"key":"53011_CR12","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1093\/eurheartj\/ehx342","volume":"38","author":"GG Schiattarella","year":"2017","unstructured":"Schiattarella, G. G. et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. Eur. Heart J. 38, 2948\u20132956 (2017).","journal-title":"Eur. Heart J."},{"key":"53011_CR13","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.4110\/in.2023.23.e6","volume":"23","author":"JH Yoon","year":"2023","unstructured":"Yoon, J. H., Do, J. S., Velankanni, P., Lee, C. G. & Kwon, H. K. Gut microbial metabolites on host immune responses in health and disease. Immune Netw. 23, e6 (2023).","journal-title":"Immune Netw."},{"key":"53011_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41584-023-01071-8","volume":"20","author":"GJ Silverman","year":"2024","unstructured":"Silverman, G. J., Azzouz, D. F., Gisch, N. & Amarnani, A. The gut microbiome in systemic lupus erythematosus: Lessons from rheumatic fever. Nat. Rev. Rheumatol. 20, 143\u2013157 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"53011_CR15","doi-asserted-by":"publisher","first-page":"1202850","DOI":"10.3389\/fimmu.2023.1202850","volume":"14","author":"K Yao","year":"2023","unstructured":"Yao, K. et al. Gut microbiota: A newly identified environmental factor in systemic lupus erythematosus. Front. Immunol. 14, 1202850 (2023).","journal-title":"Front. Immunol."},{"key":"53011_CR16","doi-asserted-by":"publisher","first-page":"1492726","DOI":"10.3389\/fimmu.2025.1492726","volume":"16","author":"Q Pan","year":"2025","unstructured":"Pan, Q., Huang, X., Liu, C., Pan, Q. & Huang, S. Systemic lupus erythematosus and atherosclerosis: Immune pathways and the uncharted territory of gut microbiota and metabolism. Front. Immunol. 16, 1492726 (2025).","journal-title":"Front. Immunol."},{"key":"53011_CR17","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Correa, C. et al. Trimethylamine N-oxide promotes autoimmunity and a loss of vascular function in toll-like receptor 7-driven lupus mice. Antioxidants (Basel). 11 (2021).","DOI":"10.3390\/antiox11010084"},{"key":"53011_CR18","first-page":"857","volume":"12","author":"Y Li","year":"2019","unstructured":"Li, Y., Liang, L., Deng, X. & Zhong, L. Lipidomic and metabolomic profiling reveals novel candidate biomarkers in active systemic lupus erythematosus. Int. J. Clin. Exp. Pathol. 12, 857\u2013866 (2019).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"53011_CR19","doi-asserted-by":"crossref","unstructured":"Chan, M. M. et al. The microbial metabolite trimethylamine N-oxide links vascular dysfunctions and the autoimmune disease rheumatoid arthritis. Nutrients. 11 (2019).","DOI":"10.3390\/nu11081821"},{"key":"53011_CR20","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2147\/JIR.S409489","volume":"16","author":"A Stec","year":"2023","unstructured":"Stec, A. et al. The gut microbial metabolite trimethylamine N-oxide is linked to specific complications of systemic sclerosis. J. Inflamm. Res. 16, 1895\u20131904 (2023).","journal-title":"J. Inflamm. Res."},{"key":"53011_CR21","doi-asserted-by":"crossref","unstructured":"Ho, K. J. et al. Elevated circulating levels of gut microbe-derived trimethylamine N-oxide are associated with systemic sclerosis. J. Clin. Med. 13 (2024).","DOI":"10.3390\/jcm13195984"},{"key":"53011_CR22","first-page":"481","volume":"37","author":"R Coras","year":"2019","unstructured":"Coras, R. et al. Choline metabolite, trimethylamine N-oxide (TMAO), is associated with inflammation in psoriatic arthritis. Clin. Exp. Rheumatol. 37, 481\u2013484 (2019).","journal-title":"Clin. Exp. Rheumatol."},{"key":"53011_CR23","unstructured":"Aringer, M. et al. European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 71, 1400\u20131412 (2019)."},{"key":"53011_CR24","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman, D. D., Iba\u00f1ez, D. & Urowitz, M. B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 29, 288\u2013291 (2002).","journal-title":"J. Rheumatol."},{"key":"53011_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/art.1780390303","volume":"39","author":"D Gladman","year":"1996","unstructured":"Gladman, D. et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 39, 363\u2013369 (1996).","journal-title":"Arthritis Rheum."},{"key":"53011_CR26","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41587-020-0548-6","volume":"38","author":"GM Douglas","year":"2020","unstructured":"Douglas, G. M. et al. PICRUSt2 for prediction of metagenome functions. Nat. Biotechnol. 38, 685\u2013688 (2020).","journal-title":"Nat. Biotechnol."},{"key":"53011_CR27","doi-asserted-by":"publisher","first-page":"D457","DOI":"10.1093\/nar\/gkv1070","volume":"44","author":"M Kanehisa","year":"2016","unstructured":"Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44, D457\u2013462 (2016).","journal-title":"Nucleic Acids Res."},{"key":"53011_CR28","doi-asserted-by":"crossref","unstructured":"Janeiro, M. H., Ramirez, M. J., Milagro, F. I., Martinez, J. A. & Solas, M. Implication of trimethylamine N-oxide (TMAO) in disease: Potential biomarker or new therapeutic target. Nutrients. 10 (2018).","DOI":"10.3390\/nu10101398"},{"key":"53011_CR29","first-page":"220","volume":"30","author":"H Kong","year":"2024","unstructured":"Kong, H. et al. Research progress in the relationship between trimethylamine oxide and coronary heart disease. Altern. Ther. Health Med. 30, 220\u2013227 (2024).","journal-title":"Altern. Ther. Health Med."},{"key":"53011_CR30","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3389\/fphar.2019.01360","volume":"10","author":"S Yang","year":"2019","unstructured":"Yang, S. et al. Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: Inflammation mechanism, clinical prognostic, and potential as a therapeutic target. Front. Pharmacol. 10, 1360 (2019).","journal-title":"Front. Pharmacol."},{"key":"53011_CR31","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.semarthrit.2013.05.003","volume":"43","author":"EJ Sutton","year":"2013","unstructured":"Sutton, E. J., Davidson, J. E. & Bruce, I. N. The systemic lupus international collaborating clinics (SLICC) damage index: A systematic literature review. Semin. Arthritis Rheum. 43, 352\u2013361 (2013).","journal-title":"Semin. Arthritis Rheum."},{"key":"53011_CR32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.46497\/ArchRheumatol.2022.9255","volume":"37","author":"D Blachut","year":"2022","unstructured":"Blachut, D. et al. The effects of glucocorticoid treatment on cardiovascular system in patients with systemic lupus erythematosus. Arch. Rheumatol. 37, 495\u2013503 (2022).","journal-title":"Arch. Rheumatol."},{"key":"53011_CR33","doi-asserted-by":"crossref","unstructured":"MacLeod, C., Hadoke, P. W. F. & Nixon, M. Glucocorticoids: Fuelling the fire of atherosclerosis or therapeutic extinguishers? Int. J. Mol. Sci. 22 (2021).","DOI":"10.3390\/ijms22147622"},{"key":"53011_CR34","doi-asserted-by":"publisher","first-page":"622225","DOI":"10.3389\/fmed.2021.622225","volume":"8","author":"JM Mej\u00eda-Vilet","year":"2021","unstructured":"Mej\u00eda-Vilet, J. M. & Ayoub, I. The use of glucocorticoids in lupus nephritis: New pathways for an old drug. Front. Med. (Lausanne). 8, 622225 (2021).","journal-title":"Front. Med. (Lausanne)"},{"key":"53011_CR35","doi-asserted-by":"publisher","first-page":"883747","DOI":"10.3389\/fimmu.2022.883747","volume":"13","author":"W Wang","year":"2022","unstructured":"Wang, W., Fan, Y. & Wang, X. Lactobacillus: Friend or foe for systemic lupus erythematosus? Front. Immunol. 13, 883747 (2022).","journal-title":"Front. Immunol."},{"key":"53011_CR36","doi-asserted-by":"publisher","first-page":"167752","DOI":"10.1016\/j.bbadis.2025.167752","volume":"1871","author":"L Huang","year":"2025","unstructured":"Huang, L. et al. Nonsurgical periodontal treatment improved the abnormal trimethylamine n-oxide metabolism in Apoe(-\/-) mice with periodontitis. Biochim. Biophys. Acta Mol. Basis Dis. 1871, 167752 (2025).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"53011_CR37","doi-asserted-by":"crossref","unstructured":"Hsu, C. N. et al. Gut microbiota-dependent trimethylamine N-oxide pathway associated with cardiovascular risk in children with early-stage chronic kidney disease. Int. J. Mol. Sci. 19 (2018).","DOI":"10.3390\/ijms19123699"},{"key":"53011_CR38","doi-asserted-by":"publisher","first-page":"1228754","DOI":"10.3389\/fimmu.2023.1228754","volume":"14","author":"Z Luo","year":"2023","unstructured":"Luo, Z. et al. Limosilactobacillus reuteri in immunomodulation: molecular mechanisms and potential applications. Front. Immunol. 14, 1228754 (2023).","journal-title":"Front. Immunol."},{"key":"53011_CR39","doi-asserted-by":"crossref","unstructured":"Laryushina, Y. et al. Alterations of the gut microbiome and TMAO levels in patients with ulcerative colitis. J. Clin. Med. 13 (2024).","DOI":"10.3390\/jcm13195794"},{"key":"53011_CR40","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.4014\/jmb.2005.05007","volume":"30","author":"SK Park","year":"2020","unstructured":"Park, S. K. et al. Reduction of trimethylamine off-odor by lactic acid bacteria isolated from Korean traditional fermented food and their in situ application. J. Microbiol. Biotechnol. 30, 1510\u20131515 (2020).","journal-title":"J. Microbiol. Biotechnol."},{"key":"53011_CR41","first-page":"e57512","volume":"16","author":"MN McPhail","year":"2024","unstructured":"McPhail, M. N. et al. A scoping review of the positive and negative bacteria associated with the gut microbiomes of systemic lupus erythematosus patients. Cureus 16, e57512 (2024).","journal-title":"Cureus"},{"key":"53011_CR42","doi-asserted-by":"crossref","unstructured":"Kim, J. W., Kwok, S. K., Choe, J. Y. & Park, S. H. Recent advances in our understanding of the link between the intestinal microbiota and systemic lupus erythematosus. Int. J. Mol. Sci. 20 (2019).","DOI":"10.3390\/ijms20194871"},{"key":"53011_CR43","doi-asserted-by":"crossref","unstructured":"Parodi, E. et al. The complex role of gut microbiota in systemic lupus erythematosus and lupus nephritis: From pathogenetic factor to therapeutic target. Microorganisms. 13 (2025).","DOI":"10.3390\/microorganisms13020445"},{"key":"53011_CR44","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1124\/dmd.116.070615","volume":"44","author":"D Fennema","year":"2016","unstructured":"Fennema, D., Phillips, I. R. & Shephard, E. A. Trimethylamine and trimethylamine N-oxide, a flavin-containing monooxygenase 3 (FMO3)-mediated host-microbiome metabolic axis implicated in health and disease. Drug Metab. Dispos. 44, 1839\u20131850 (2016).","journal-title":"Drug Metab. Dispos."},{"key":"53011_CR45","doi-asserted-by":"publisher","first-page":"e23743","DOI":"10.1016\/j.heliyon.2023.e23743","volume":"10","author":"W Zhang","year":"2024","unstructured":"Zhang, W. et al. Microbiome signatures in ischemic stroke: A systematic review. Heliyon 10, e23743 (2024).","journal-title":"Heliyon"},{"key":"53011_CR46","doi-asserted-by":"crossref","unstructured":"Zhang, B., Wang, X., Xia, R. & Li, C. Gut microbiota in coronary artery disease: A friend or foe? Biosci. Rep. 40 (2020).","DOI":"10.1042\/BSR20200454"},{"key":"53011_CR47","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1253\/circj.CJ-15-0526","volume":"79","author":"T Yamashita","year":"2015","unstructured":"Yamashita, T. et al. Intestinal immunity and gut microbiota as therapeutic targets for preventing atherosclerotic cardiovascular diseases. Circ. J. 79, 1882\u20131890 (2015).","journal-title":"Circ. J."},{"key":"53011_CR48","doi-asserted-by":"crossref","unstructured":"Suswa\u0142, K. et al. Gut-lung axis in focus: Deciphering the impact of gut microbiota on pulmonary arterial hypertension. J. Pers. Med. 14 (2023).","DOI":"10.3390\/jpm14010008"},{"key":"53011_CR49","doi-asserted-by":"crossref","unstructured":"Barrea, L. et al. Association of the chronotype score with circulating trimethylamine N-oxide (TMAO) concentrations. Nutrients. 13 (2021).","DOI":"10.3390\/nu13051671"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53011-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53011-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53011-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:17:58Z","timestamp":1785518278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53011-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["53011"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-53011-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23438"}}